Orthocell Ltd
AASX:OCCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Orthocell Limited (ASX: OCC) is a biotechnology company focused on developing and commercializing regenerative medicines and tissue repair technologies for musculoskeletal conditions. The company offers a portfolio of proprietary products including CelMatrix, an equine collagen scaffold for tendon and ligament repair; Ortho-ACI, an autologous chondrocyte implantation therapy for cartilage regeneration; and Collagen Meniscus Implant for meniscus reconstruction; along with research-stage platforms such as Remplir for tendon reconstruction and ICS for interpositional cartilage scaffold. Orthocell targets orthopedic surgeons, sports medicine professionals, and veterinary practitioners, operating primarily in Australia, the United States, and Europe from its headquarters in Murdoch, Western Australia, where it was founded in 2006. Recent developments include expanded clinical adoption of CelMatrix in equine veterinary applications and ongoing Phase 3 trials for Ortho-ACI Max, alongside strategic collaborations with leading orthopedic centers to accelerate commercialization efforts in the past two years.
Company News
Orthocell US expansion supports record revenue - ICYMI
Twin Vee PowerCats shares surge after merger agreement to combine public company with USFM subsidiary
Orthocell delivers record FY2026 revenue as US Remplir rollout accelerates
Small Cap Watch: Orthocell posts record revenue and explorers advance Queensland and Greenland programs
Microsoft axes 2% of workforce as 'AI is changing how work gets done'
Nine Mile Metals signs market-making and media agreements
Amazon AWS launches new AI engineering division with $1B commitment
FTSE 100 Live: London blue-chips hit 10-week high as Sainsbury's and miners climb
Abivax shares jump as updated trial data eases safety concerns
Orthocell's Remplir achieves 90% success rate in real-world patient data - ICYMI
UBS has strong cloud growth expectations ahead of hyperscaler earnings
Orthocell's Remplir moves Into US military healthcare - ICYMI
Newmont beats quarterly profit estimates on strong gold prices
Blue Star shares drop after hack exploits SatoshiPay liquidity pools
Amazon faces margin questions despite expected Q1 revenue beat
Orthocell flags strong March quarter as US Remplir rollout gathers pace
US-Iran peace deal seen as months away as prediction markets give just 24% chance of agreement this week
Orthocell completes first Remplir case in US military hospital network
Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
Orthocell secures access to US military and veterans hospital network for Remplir